Patient with Major Depressive Disorder Responds to L-Methylfolate Post-Genetic Testing

Depression is the leading cause of disability world-wide, affecting approximately 350 million people. Several studies have found that about 70% of patients with depression treated with first-line therapies show some level of response; however, 30% ofpatients remain refractory to treatments leading to poor quality of life andimpairment in overall functioning. There are numerous factors that contribute to treatment resistance including depression severity, number of psychiatric and medical comorbidities, environmental factors such as family conflict, maternal depression, history of physical or sexual abuse, as well as genetic vulnerabilities. 

It has long been recognized that there is substantial variation of psychiatric treatment response. Understanding an individual’s genetic background can help to predict drug response and potential risk for adverse health events. Case Report  : A 69-year old Caucasian male presented to a psychiatric nurse practitioner with sadness, negative and perseverative thinking, and sleep difficulties. He reported sleep onset insomnia and frequent awakenings. The patient complained of fatigue, low energy, and lack of interest in activities. He reported a decreased ability to concentrate and complained of ongoing procrastination in his activities and interference with his longstanding hobbies. Read more............